Programa de trasplantes de riñón

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. A Study to Identify Physical Function Trajectories and Biomarkers after Kidney Transplantation

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The aims of this study are to identify frailty trajectories and biomarkers of frailty after kidney transplantation. Subjects will be followed beginning immediately prior to kidney transplantation until 1 year after kidney transplantation. Frailty will be prospectively assessed using performance-based measures (Fried criteria and Short Physical Impairment Battery). The relationship between frailty measures and blood levels of promising candidate biomarkers will be analyzed.

2. Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.

3. A Study of Study of Immune Tolerance Mechanisms in Kidney Transplant Patients

   Scottsdale/Phoenix, Ariz.

   Hypothesis: we hypothesize that the abundance and functions of Breg subsets in kidney transplant patients could be associated with transplant tolerance and rejection, including DSA-mediated kidney transplant rejection. In addition, oral corticosteroid treatment significantly alters the frequency and function of Breg subsets, which could lead altered clinical outcomes.
   
   Aims, purpose, or objectives:
   1. Investigate the frequency Bregs and their ability to express IL-10 along with other immune cells in the context of tolerance/rejection in kidney transplant patients.
   we hypothesize that the abundance and functions of Breg subsets in kidney transplant patients could be associated with transplant tolerance and rejection, including DSA-mediated kidney transplant rejection.
   
   2.Investigate the frequency and functions of Bregs along with other immune cells in the setting of long term corticosteroid use.
   We hypothesize that oral corticosteroid treatment significantly alters the frequency and function of Breg subsets, which could lead altered clinical outcomes.

4. Exercise to Treat Frailty in Kidney Transplant Candidates

   Rochester, Minn.

   Frailty is a condition characterized by slowness, weakness, low physical activity, wasting, and exhaustion. Frailty increases the risk for adverse outcomes following transplant such as increased length of stay in the hospital, mortality, or graft function. No interventions for frailty are known for patients with renal disease, but exercise programs like pulmonary rehabilitation have been effective in improving frailty in patients with other diseases, such as lung disease. The goal of this study is to test whether exercise will also improve frailty among patients who are waiting for a kidney transplant and who are considered frail or pre-frail.

5. A Study to Evaluate the Safety and Effectiveness of Once-Daily Envarsus XR® and Twice-Daily, Immediate-Release Tacrolimus in Adult Renal Transplant Recipients

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to compare tacrolimus formulations (Envarsus XR® versus twice a day tacrolimus) with the hypothesis that Envarsus XR® improves transplant- and tacrolimus- associated symptoms when compared to a twice a day tacrolimus regimen.

6. A Study to Assess the Updated Prospera™ Diagnostic Test

   Scottsdale/Phoenix, Ariz.

   The purpose of this study to collect blood samples and data to assess the diagnostic capability of an updated version of the Prospera™ test.  The current standard of care for detection of rejection in renal allograft recipients is serum creatinine, often used in combination with other blood tests such as proteinuria. Natera has developed an assay called Prospera™ to detect the amount of donor-derived cell-free DNA (dd-cfDNA), which is a marker of kidney rejection.

7. A Study to Evaluate Alloantibody Titer in Highly Sensitized Kidney Transplant Candidates

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the utility of using anti-HLA antibody titer to measure the effectiveness of antibody lowering therapy (i.e., desensitization) in highly-sensitized kidney transplant candidates.

    

8. A Study to Evaluate Patient Outcomes From the Kidney Allograft Outcomes AlloSure® Registry

   Jacksonville, Fla.

   The purpose of this study is to evaluate safety and efficacy outcomes in renal transplant recipients in whom post-transplant care is managed using AlloSure®. AlloSure® is a non-invasive test to measure donor-derived cell-free DNA (dd-cfDNA). The AlloSure test is intended to assess the probability of allograft rejection in kidney transplant recipients with clinical suspicion of rejection and to inform clinical decision-making regarding the necessity of renal biopsy in such patients at least 2 weeks post-transplant in conjunction with standard clinical assessment. Amendment 1 (A1): Is an observational study to develop and validate the clinical use of KidneyCare®.

9. A Study to Assess Reproductive History in Kidney Donors

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to analyze the effect of parity, menopause and reproductive lifespan on kidney structure and function.

10. A Study to Evaluate Ultrasound Imaging in Renal Transplant Recipients

    Jacksonville, Fla.

    The purpose of this study is to determine the effectiveness of ultrasound elastography in prediction of renal allograft fibrosis.